Insider Trading (Form 4)
NASDAQ
Organigram Holdings Inc. reports a 6% increase in fiscal 2024 net revenue and a record adjusted EBITDA of $5.9 million in Q4, becoming Canada's largest cannabis company by market share after acquiring Motif Labs.
Capital raise
Better than expected
NASDAQ
Organigram Holdings Inc. reports a 6% increase in net revenue for fiscal 2024, alongside a record adjusted EBITDA of $5.9 million in Q4, and becomes Canada's largest cannabis company by market share following the acquisition of Motif Labs.
Capital raise
Better than expected
Schedule 13D - Activist Investments
NASDAQ
British American Tobacco has expanded its investment in Organigram Global Inc. following the acquisition of Sanity Group GmbH and a concurrent private placement.
Capital raise
NASDAQ
SCHEDULE 13D/A: Organigram Global Acquires Sanity Group; BAT Boosts Stake
Organigram Global Inc. is set to fully acquire Sanity Group GmbH, with British American Tobacco's subsidiary increasing its strategic investment through a share-based consideration and a significant private placement.
Capital raise
NASDAQ
SCHEDULE 13D/A: British American Tobacco Subsidiary Completes Strategic Investment in Organigram Holdings, Securing 30% Common Share Stake
BT DE Investments Inc., a subsidiary of British American Tobacco p.l.c., has finalized its multi-tranche private placement in Organigram Holdings Inc., increasing its beneficial ownership to 30% of common shares and 100% of preferred shares.
Capital raise